دورية أكاديمية
Incretin-based drugs and hospitalization for heart failure in the clinical practice : a nested case-control study
| العنوان: | Incretin-based drugs and hospitalization for heart failure in the clinical practice : a nested case-control study |
|---|---|
| المؤلفون: | C. Santucci, M. Franchi, L. I. Staszewsky, C. La Vecchia, R. Latini, L. Merlino, G. Corrao, C. Bosetti |
| المساهمون: | C. Santucci, M. Franchi, L.I. Staszewsky, C. La Vecchia, R. Latini, L. Merlino, G. Corrao, C. Bosetti |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2018 |
| المجموعة: | The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| مصطلحات موضوعية: | Diabete, dipeptidyl peptidase 4 inhibitor, glucagon-like peptide-1 receptor agonist, heart failure, incretin-based drug, pharmacoepidemiology, Settore MED/01 - Statistica Medica |
| الوصف: | Background and aims: There are concerns that incretin-based antidiabetic drugs - including dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists -increase the risk of hospitalization for heart failure (HF). To further analyse this issue, we conducted a nested case-control study within a cohort of antidiabetic users in a real world setting. Methods and results: Within a cohort of 133,639 subjects with a first prescription of an antidiabetic drug (new-users) between 2010 and 2016 in Lombardy, Italy, and were followed-up to 2016, we identified 4057 subjects with a first hospitalization for HF and 80,450 controls matched on sex, age, and date of cohort-entry. The multivariate odds ratios (ORs) of HF in relation to current use of incretin-based drugs as compared to current use of two or more oral antidiabetics was 1.06 (95% confidence interval, CI, 0.83-1.35), with no evidence of a trend in risk with increasing duration of use. The corresponding ORs were 1.10 (95% CI 0.85-1.41) for DPP-4 inhibitors and 0.84 (95% CI 0.48-1.47) for GLP-1 receptor agonists. Estimates were consistent in various sensitivity analyses. Conclusions: This study indicates that incretin-based drugs are not associated with an increased risk of hospitalization for HF, thus providing further reassurance on the cardiovascular safety of these antidiabetic drugs in the clinical practice. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/30332619; info:eu-repo/semantics/altIdentifier/wos/WOS:000452704800020; volume:146; firstpage:172; lastpage:179; numberofpages:8; journal:DIABETES RESEARCH AND CLINICAL PRACTICE; http://hdl.handle.net/2434/596355Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85055737730 |
| DOI: | 10.1016/j.diabres.2018.10.006 |
| الإتاحة: | https://doi.org/10.1016/j.diabres.2018.10.006Test http://hdl.handle.net/2434/596355Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.625FB7F1 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.diabres.2018.10.006 |
|---|